Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
DRUG

Fludarabine

DRUG

Cyclophosphamide

DRUG

Rituximab

DRUG

Pentostatin

Trial Locations (11)

12208

New York Oncology Hematology, PC, Albany

18704

Medical Oncology Associates, Kingston

21157

Alliance Hematology Oncology PA, Westminster

28602

Northwestern Carolina Oncology Hemato, Hickory

34761

Cancer Centers of Florida, P.A., Ocoee

47802

Hope Center, Terre Haute

64507

St Joseph Oncology, Inc, Saint Joseph

77479

Texas Oncology Cancer Center-Sugar Land, Sugar Land

78503

South Texas Cancer Center-McAllen, McAllen

98902

Yakima Valley Mem Hosp/North Star Lodge, Yakima

99202

Cancer Care Northwest-South, Spokane

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

US Oncology Research

INDUSTRY